Health Journal Online

Tag: Exposure

  • FDA Approves Xocova (Ensitrelvir): The First Oral COVID Pill You Take After Exposure — Before You Get Sick

    FDA Approves Xocova (Ensitrelvir): The First Oral COVID Pill You Take After Exposure — Before You Get Sick

    COVID-19 is still killing tens of thousands of Americans every year — and for the first time, there is now an FDA-approved oral medication that household contacts of infected individuals can take before symptoms develop to significantly reduce their risk of getting sick.

    On June 1, 2026, the U.S. Food and Drug Administration approved Xocova® (ensitrelvir), an oral antiviral developed by Japanese pharmaceutical company Shionogi, for post-exposure prophylaxis (PEP) of COVID-19 in adults and adolescents 12 years of age and older. It is the first and only oral option approved for preventing COVID-19 after exposure to an infected individual — a distinct and previously unaddressed clinical need.

    What Xocova Is — and How It Differs From Paxlovid

    The distinction between Xocova and Paxlovid (nirmatrelvir/ritonavir) is essential to understand, because they serve different purposes at different points in the COVID-19 timeline.

    Paxlovid is taken after a positive COVID test and symptom onset, to reduce the severity of illness in high-risk individuals who are already sick. It is a treatment for active disease.

    Xocova is taken after exposure to an infected individual, before the person becomes infected or symptomatic — a pre-symptomatic intervention window that previously had no oral pharmacological option in the United States. It is a prophylactic medication, not a treatment for existing infection.

    Mechanistically, both drugs target the same SARS-CoV-2 main protease (3CL protease) — a key enzyme the virus needs to replicate. By blocking this enzyme, Xocova prevents the virus from reproducing efficiently in newly exposed individuals, reducing the probability that a household exposure leads to established infection.

    According to the SCORPIO-PEP trial data published in the New England Journal of Medicine: in the primary endpoint analysis of 2,041 SARS-CoV-2-negative participants, only 2.9% of those in the ensitrelvir group developed symptomatic COVID-19 by day 10, compared with 9.0% in the placebo group — a 67% reduction in risk.

    Xocova (Ensitrelvir) Key Data Detail
    FDA approval date June 1, 2026
    Developer Shionogi (Japan)
    Indication Post-exposure prophylaxis (PEP) of COVID-19
    Age indication Adults and adolescents 12 years and older
    Phase 3 trial SCORPIO-PEP (NCT05897541)
    Primary endpoint result 67% lower risk of symptomatic COVID-19 (2.9% vs. 9.0%)
    Secondary analysis (all participants) 57% risk reduction
    Dosing regimen 375mg on Day 1 (3 tablets); then 125mg on Days 2–5 (1 tablet each)
    Duration 5 days
    Most common side effects Headache, diarrhea, cough (15.1% vs. 15.5% placebo)
    Prior approved COVID post-exposure option None (bamlanivimab withdrawn due to Omicron resistance)
    U.S. COVID cases Oct 2025 – May 2026 3.8–12.4 million (CDC estimate)
    U.S. COVID deaths Oct 2025 – May 2026 13,000–42,000 (CDC estimate)

    How the Trial Worked — and What the Results Mean

    The SCORPIO-PEP trial enrolled 2,387 individuals aged 12 and older who had tested negative for SARS-CoV-2 at enrollment and were living in a household with a confirmed COVID-19 case. Participants were randomized 1:1 to receive ensitrelvir or matching placebo for five days.

    According to AJMC, ensitrelvir was well tolerated — adverse event rates were nearly identical between the ensitrelvir group (15.1%) and placebo group (15.5%), with the most common events being headache, diarrhea, and cough. No serious safety signals were identified.

    A notable feature of the trial population: more than 99% of household contacts already had SARS-CoV-2 antibodies at baseline — meaning nearly the entire study population had pre-existing immunity from prior infection, vaccination, or both. TechTimes noted that the drug performed equally well in this highly immune population, confirming that Xocova’s benefit does not depend on immunological naivety. This is clinically significant: it means the medication is likely to work in 2026’s real-world population, nearly all of whom have some prior COVID immunity.

    Who Should Take Xocova — and When

    The critical timing parameter for Xocova is not yet formally defined by the FDA label as a specific hour cutoff, but the clinical logic — and the trial design — centers on initiating treatment as soon as possible after a confirmed household exposure, ideally within 24 to 72 hours.

    The populations with the most to gain include:

    • Adults 60 and older, who remain at highest risk of severe COVID outcomes
    • Immunocompromised individuals (transplant recipients, patients on chemotherapy, people with HIV, those on long-term immunosuppressive therapy)
    • Adults with significant comorbidities — heart disease, diabetes, chronic kidney disease, chronic lung disease, obesity
    • Residents and staff of long-term care facilities, where up to 47% of household-level contacts develop COVID following exposure to an infected person, according to Shionogi’s prescribing data
    • Adolescents 12 and older in high-risk households

    Anyone in one of these groups who has a confirmed household contact with COVID-19 should contact their healthcare provider immediately to discuss Xocova eligibility. The drug closes a therapeutic gap that has existed since bamlanivimab/etesevimab — the only prior authorized COVID post-exposure option — was withdrawn after proving ineffective against Omicron variants.

    “The approval for COVID-19 PEP was based on data from the SCORPIO-PEP trial, which demonstrated favorable safety and efficacy in uninfected pediatric and adult patients who had been exposed to an infected individual, reducing the risk of symptomatic COVID-19 by 67%,” AJMC reported.

    COVID-19 in 2026 — Why This Still Matters

    The approval arrives at a moment when COVID-19 has become background noise for many Americans but remains a significant cause of illness, hospitalization, and death. The CDC estimates that between October 1, 2025, and May 23, 2026, there were 3.8 to 12.4 million new COVID cases in the United States, resulting in 800,000 to 2.3 million outpatient visits, 120,000 to 240,000 hospitalizations, and 13,000 to 42,000 deaths. Long COVID — which produces lasting neurological, cardiovascular, and respiratory complications — adds a further layer of risk that prevention reduces. Preventing even a percentage of those infections among the highest-risk population represents a meaningful public health gain.

    Frequently Asked Questions

    What is Xocova (ensitrelvir) and what was it approved for?

    Xocova (ensitrelvir) was FDA-approved June 1, 2026, by Shionogi, as the first and only oral medication for post-exposure prophylaxis (PEP) of COVID-19. It is approved for adults and adolescents 12 and older who have had contact with a confirmed COVID-19 case.

    How is Xocova different from Paxlovid?

    Paxlovid is taken after a positive COVID test and symptom onset to reduce disease severity. Xocova is taken after exposure but before infection or symptom onset, to prevent the exposed person from developing COVID at all. They target the same viral enzyme but are used at different clinical moments.

    How effective is Xocova?

    In the Phase 3 SCORPIO-PEP trial, Xocova reduced the risk of symptomatic COVID-19 by 67% compared to placebo in household contacts who were initially SARS-CoV-2-negative, with a secondary analysis showing 57% risk reduction across all participants.

    How do you take Xocova?

    Xocova is a 5-day oral regimen: 3 tablets taken as a single dose on Day 1, then 1 tablet per day on Days 2 through 5. It should be started as soon as possible after a confirmed household exposure. Contact your healthcare provider immediately if you have been exposed.

    Who qualifies for Xocova?

    The FDA approval covers adults and adolescents 12 and older following contact with a confirmed COVID-19 case. People most likely to benefit include adults 60 and older, the immunocompromised, those with significant comorbidities, and long-term care residents and staff. A healthcare provider should assess individual eligibility.

    Source link

  • Cytotoxic Drug Exposure, Genotoxicity, and the Unseen Risk to Autism

    Cytotoxic Drug Exposure, Genotoxicity, and the Unseen Risk to Autism

    For more than two decades, Jim Mullowney has been sounding the alarm about a problem many don’t want to confront: the hidden risks associated with human waste from cytotoxic drugs. As the founder of Pharma-Cycle, a company dedicated to providing safe collection and disposal systems for the urine, feces, and vomit of patients containing cytotoxic drugs, Mullowney has devoted his career to preventing birth defects, including autism, childhood cancer, and others.

    “I first realized what we were dealing with when I saw syringes full of chemotherapy drugs being mishandled at a hazardous waste facility,” recalls Mullowney. “These were not ordinary chemicals; many of them are cytotoxic, designed to alter the DNA of rapidly dividing cells, such as a child being born. They are life-saving in the right medical context, but their second-hand exposure is disastrous.”

    Cytotoxic drugs are indispensable in cancer care. They aim to target rapidly dividing cancer cells. But their second-hand potency has an enormous duality. While essential in treatment, their genotoxic nature means they can affect other fast-growing healthy cells, such as those in hair, skin, or the reproductive system of men and women of childbearing age, a known risk to fertility. This presents a major public health challenge because these hazardous agents can be shed by patients not just in urine and feces, but also in sweat, vomit, and saliva. That duality, which is at the heart of their therapeutic power yet makes them hazardous outside strict controls, is the undeniable reality at the core of Mullowney’s mission.

    “The reality is that hospitals handle these substances with extraordinary caution,” he explains. “You will see pharmacists working behind multi-million-dollar systems with robots mixing doses in sealed environments. Nurses wear protective gear. But after a patient receives treatment, they go home, and just like the vitamin you took this morning, where your urine looks like you ate a highlighter, the drugs continue to leave their system. That’s where the oversight drops off.”

    Mullowney also raises questions about potential connections between environmental exposures and conditions such as autism. While autism is widely understood as a complex neurodevelopmental condition with both genetic and environmental influences, Mullowney believes the role of hazardous drugs in shaping DNA deserves closer examination. “If autism has a genetic component, and we know certain chemicals are designed specifically to alter DNA, then it’s at least worth asking what impact secondhand exposure to cytotoxic drugs could have,” he says. Although no definitive link has been established, he argues that the issue highlights the need for expanded research into how these substances may affect future generations.

    Scientific literature has documented for decades that cytotoxic drugs are hazardous even in small amounts. The United States Pharmacopoeia, known as USP800, has long recognized the risks to healthcare workers under USP Chapter 800 exposed during preparation or administration. Mullowney believes the same awareness needs to extend beyond the hospital walls.

    “We know these drugs are excreted in sweat, urine, and stool,” he says. “Once outside controlled settings, they don’t just disappear. They can end up in wastewater, septic systems, and even on household surfaces. That raises questions about who else could be exposed, and what the long-term consequences might be.”

    While research has shown increased rates of miscarriage and birth defects among healthcare workers exposed to cytotoxic drugs, the broader impact on families and communities is less well studied. “Nobody disputes the toxicity of these substances,” he notes. “The gap is in connecting that knowledge to how we manage drug waste once patients leave the hospital.”

    Pharma-Cycle was founded to address precisely that gap. The company develops collection systems that aim to safely capture hazardous pharmaceutical waste before it contaminates our families and future generations, as well as enters the environment. “The simplest way to put it,” Mullowney explains, “is that we can’t treat these drugs like ordinary trash. They need a closed-loop system, collected, contained, and destroyed in a way that protects public health.”

    The challenge, he admits, is not technological but political. “The science is there. Various well-known safety and health agencies have recognized the dangers of cytotoxic drugs for decades. What’s missing is the will to standardize and enforce proper collection. Too often, regulatory agencies pass responsibility back and forth, and the result is inaction.”

    Mullowney believes broader change requires public awareness. “Most people don’t know this issue exists,” he says. “Hazardous cytotoxic drug waste rarely makes headlines.”

    That’s why he continues to advocate, not only as a business owner but as a father. “I’m not doing this for money,” Mullowney says. “I’m doing it because I have seen what these chemicals are and how poorly they have been handled. If we know these drugs can be harmful in microdoses, why aren’t we taking every step to prevent unnecessary exposure?”

    For Mullowney, the path forward is clear: improve public understanding, strengthen regulations, and implement proven systems for safe disposal. “We put a car on the moon,” he says, “but we still have not figured out how to consistently keep cytotoxic drugs out of our environment. That needs to change.”

    The urgency of his message is not rooted in alarmism but in precaution. As he says, “These are lifesaving medicines, and we will always need them. But if we don’t handle the waste responsibly, we could risk creating problems for future generations, including autism and other birth defects. Prevention is always better than repair.”

    Source link

  • Childhood Exposure To Common Gut Bacteria To Blame?

    Childhood Exposure To Common Gut Bacteria To Blame?

    Colorectal cancer rates are climbing globally, with a particularly alarming rise among young adults under 50. Researchers now believe they may have uncovered a hidden culprit behind the medical mystery. A recent study suggests that early exposure to a toxin produced by harmful strains of E. coli could be a possible driver behind the surge.

    In the latest study published in the journal Nature, researchers found that childhood exposure to colibactin, a toxin produced by certain strains of E.coli, damages DNA and these mutations raise the risk of bowel cancer before the age of 50.

    In a large-scale genome analysis of 981 colorectal cancer across 11 countries, researchers noted a distinct pattern of DNA mutations caused by colibactin. These specific DNA patterns were over three times more common in patients under 40 compared to those over 70.

    Interestingly, these genetic fingerprints were not just seen in young adults, but more often in countries with the highest rates of early-onset colorectal cancer, pointing to a possible link between bacterial exposure and the rising number of young adults affected worldwide.

    “These mutation patterns are a kind of historical record in the genome, and they point to early-life exposure to colibactin as a driving force behind early-onset disease,” said study senior author Ludmil Alexandrov in a news release.

    “If someone acquires one of these driver mutations by the time they’re 10 years old, they could be decades ahead of schedule for developing colorectal cancer, getting it at age 40 instead of 60,” Alexandrov explained.

    While earlier studies including prior research from the same team had linked colibactin to 10 to 15 percent of all colorectal cancer cases, they did not differentiate between younger and older patients.

    “When we started this project, we weren’t planning to focus on early-onset colorectal cancer. Our original goal was to examine global patterns of colorectal cancer to understand why some countries have much higher rates than others. But as we dug into the data, one of the most interesting and striking findings was how frequently colibactin-related mutations appeared in the early-onset cases,” said the first author Marcos Díaz-Gay.

    Researchers are now exploring innovative ways to translate these findings into early detection and prevention tools. One promising idea is a stool test designed to detect colibactin-related markers, which could help identify individuals at higher risk for early-onset colorectal cancer. They are also investigating the potential of probiotic therapies aimed at rebalancing the gut microbiome in children to reduce the risk later in life.

    Source link

  • Exposure To Air Pollution During Pregnancy And Childhood Have Lasting Effects On Brain: Study

    Exposure To Air Pollution During Pregnancy And Childhood Have Lasting Effects On Brain: Study

    Long-term exposure to air pollutants is known to affect physical well-being, increasing the risk of respiratory illnesses, cardiovascular diseases, and cancers. A recent study revealed that early-life exposure to air pollution has lasting effects on the brain.

    According to the research led by the Barcelona Institute for Global Health (ISGlobal), exposure to fine particles (PM2.5) and nitrogen oxides (NOx) during pregnancy and childhood can lead to significant changes in the microstructure of the brain’s white matter. Alarmingly, these alterations can persist into adolescence, raising concerns about the long-term impact of air pollution on brain development.

    Earlier studies have explored the impact of air pollutants on the brain’s white matter, but most were limited to a single time point and did not track participants throughout childhood.

    The latest study published in Environmental Research involved 4,000 participants in Rotterdam, the Netherlands who were part of the Generation R Study and were followed up since birth. Based on the participants’ location, the team estimated the amount of exposure to 14 different air pollutants during pregnancy and childhood.

    To examine changes in white matter microstructure, researchers conducted brain scans on 1,314 children, once around the age of 10 and again around 14.

    “Following participants throughout childhood and including two neuroimaging assessments for each child would shed new light on whether the effects of air pollution on white matter persist, attenuate, or worsen,” said ISGlobal researcher Mònica Guxens in a news release.

    The results revealed that higher exposure to PM2.5 during pregnancy, as well as elevated levels of PM2.5, PM10, PM2.5-10, and NOx during childhood, led to a reduction in fractional anisotropy, a measure of how water molecules diffuse within the brain. In more mature brains, water tends to flow more in one direction, resulting in higher values for this marker. This association persisted into adolescence, indicating a long-term impact of air pollution on brain development.

    “Every increase in exposure level to air pollution corresponded to more than a 5-month delay in the development of fractional anisotropy,” the researchers wrote.

    “We think that the lower fractional anisotropy is likely the result of changes in myelin, the protective sheath that forms around the nerves, rather than in the structure or packaging of the nerve fibers,” said first author of the study, Michelle Kusters.

    Source link